Bryan Cox
Directeur Technique/Scientifique/R&D chez TRISALUS LIFE SCIENCES, INC.
Fortune : 860 891 $ au 30/04/2024
Profil
Bryan F.
Cox is currently the Chief Executive Officer at Nephraegis Therapeutics, Inc. and the Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. Previously, he worked as the Director-Integrative Pharmacology at Abbott Laboratories from 1996 to 2013.
Dr. Cox holds a doctorate degree from the University of Iowa and an undergraduate degree from The University of North Carolina at Chapel Hill.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/02/2024 | 86 696 ( 0,32% ) | 860 891 $ | 30/04/2024 |
Postes actifs de Bryan Cox
| Sociétés | Poste | Début |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Directeur Technique/Scientifique/R&D | 10/08/2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Directeur Général | 01/11/2018 |
Anciens postes connus de Bryan Cox
| Sociétés | Poste | Fin |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/2013 |
Formation de Bryan Cox
| University of Iowa | Doctorate Degree |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |